Shares

14 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 15, 2024

SELL
$6.87 - $26.45 $6.3 Million - $24.2 Million
-916,478 Reduced 42.83%
1,223,472 $11 Million
Q4 2023

Feb 14, 2024

BUY
$11.28 - $25.46 $2.47 Million - $5.58 Million
219,292 Added 11.42%
2,139,950 $53.2 Million
Q3 2023

Nov 14, 2023

SELL
$16.34 - $24.66 $6.01 Million - $9.07 Million
-367,835 Reduced 16.07%
1,920,658 $31.9 Million
Q2 2023

Aug 14, 2023

SELL
$16.06 - $21.61 $50,026 - $67,315
-3,115 Reduced 0.14%
2,288,493 $42.8 Million
Q1 2023

May 15, 2023

BUY
$17.19 - $30.8 $8.47 Million - $15.2 Million
492,653 Added 27.39%
2,291,608 $42.1 Million
Q4 2022

Feb 14, 2023

BUY
$16.28 - $24.6 $1.4 Million - $2.11 Million
85,821 Added 5.01%
1,798,955 $35.6 Million
Q3 2022

Nov 14, 2022

SELL
$17.96 - $30.46 $3.6 Million - $6.11 Million
-200,657 Reduced 10.48%
1,713,134 $41.2 Million
Q2 2022

Aug 15, 2022

SELL
$10.26 - $23.59 $9.09 Million - $20.9 Million
-886,171 Reduced 31.65%
1,913,791 $34.9 Million
Q1 2022

May 16, 2022

SELL
$17.02 - $40.22 $2.17 Million - $5.13 Million
-127,603 Reduced 4.36%
2,799,962 $61.6 Million
Q4 2021

Feb 14, 2022

BUY
$29.5 - $39.5 $590,000 - $790,000
20,000 Added 0.69%
2,927,565 $108 Million
Q3 2021

Nov 15, 2021

BUY
$29.86 - $39.47 $12.9 Million - $17 Million
431,905 Added 17.45%
2,907,565 $90.3 Million
Q2 2021

Aug 16, 2021

SELL
$17.99 - $40.02 $32,759 - $72,876
-1,821 Reduced 0.07%
2,475,660 $78.7 Million
Q1 2021

May 17, 2021

BUY
$16.0 - $24.46 $14.4 Million - $22 Million
900,000 Added 57.05%
2,477,481 $55 Million
Q4 2020

Feb 16, 2021

BUY
$15.89 - $40.87 $25.1 Million - $64.5 Million
1,577,481 New
1,577,481 $31.2 Million

Others Institutions Holding RAPT

About RAPT Therapeutics, Inc.


  • Ticker RAPT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 29,656,600
  • Market Cap $35.6M
  • Description
  • RAPT Therapeutics, Inc., a clinical-stage immunology-based biopharmaceutical company, focuses on discovering, developing, and commercializing oral small molecule therapies for patients with unmet needs in oncology and inflammatory diseases. Its lead inflammation drug candidate is RPT193, a C-C motif chemokine receptor 4 (CCR4) antagonist that se...
More about RAPT
Track This Portfolio

Track Perceptive Advisors LLC Portfolio

Follow Perceptive Advisors LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Perceptive Advisors LLC, based on Form 13F filings with the SEC.

News

Stay updated on Perceptive Advisors LLC with notifications on news.